| abstract |
Gap identified in the treatment of ketamine for symptoms such as pain, depression, traumatic brain injury, stroke, epilepsy, alcoholism or Alzheimer's disease that do not result in neurological toxicity (eg, psychiatric onset toxicity). A controllable norketamine compound and a preparation containing the same are provided. SOLUTION: For example, it is a compound having a structure according to any of the following formulas. [Selection diagram] None |